Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2005 December 1; 115(12): 3573–3578.
PMCID: PMC1297252

Absence of ghrelin protects against early-onset obesity


The gut peptide ghrelin, the endogenous ligand for the growth hormone secretagogue receptor, has been implicated not only in the regulation of pituitary growth hormone (GH) secretion but in a number of endocrine and nonendocrine functions, including appetitive behavior and carbohydrate substrate utilization. Nevertheless, recent genetic studies have failed to show any significant defects in GH levels, food intake, or body weight in adult ghrelin-deficient (Ghrl−/−) mice. Here we demonstrate that male Ghrl−/− mice are protected from the rapid weight gain induced by early exposure to a high-fat diet 3 weeks after weaning (6 weeks of age). This reduced weight gain was associated with decreased adiposity and increased energy expenditure and locomotor activity as the animals aged. Despite the absence of ghrelin, these Ghrl−/− mice showed a paradoxical preservation of the GH/IGF-1 axis, similar to that reported in lean compared with obese humans. These findings suggest an important role for endogenous ghrelin in the metabolic adaptation to nutrient availability.


Ghrelin is a 28-aa peptide produced predominantly by the stomach and is the endogenous ligand for the growth hormone secretagogue receptor (GHSR) (1). In addition to potently stimulating growth hormone (GH) secretion from the pituitary (1), ghrelin administration stimulates food intake (2, 3) and carbohydrate utilization (2) and increases adiposity in rodents (2), suggesting a role for this hormone in energy balance. Consistent with this idea, ghrelin levels are modulated by changes in nutritional status, such as food deprivation (2) or exposure to a high-fat diet (HFD) (4, 5). Further, GHSR is colocalized with neuropeptide Y/agouti-related protein (NPY/AgRP) neurons in the arcuate nucleus of the hypothalamus (6), an area that is responsive to circulating nutrients and hormones related to energy balance (7). The finding that ghrelin stimulates the spontaneous activity of these neurons (8) and increases NPY and AgRP gene expression (9) indicates that this hormone may mediate its effects on food intake and metabolic parameters via interactions with these peptide systems.

However, a recent study of ghrelin-deficient mice by Sun et al. (10) failed to identify any disturbances in growth rate, food intake, or body composition in these mice on either a standard or HFD and found no difference in their behavioral response to a period of food deprivation. A further study by this group also found normal growth rate, food intake, and body composition in Ghsr-deficient mice (11). Thus, these genetic studies question the role of endogenous ghrelin in regulating energy balance and the suitability of the ghrelin pathway as a target for potential antiobesity therapies.

In agreement with Sun et al. (10), we previously reported that ghrelin-deficient (Ghrl–/–) mice exhibit normal spontaneous food intake patterns and normal basal levels of hypothalamic orexigenic and anorexigenic neuropeptides, with no impairment in feeding (12), indicating that endogenous ghrelin has, at most, a redundant role in the regulation of appetite. However, further analyses of adult Ghrl–/– mice on a HFD demonstrated that endogenous ghrelin plays a prominent role in determining the type of metabolic substrate used to maintain energy balance (i.e., fat vs. carbohydrate). Although a trend toward a lean phenotype on the HFD was apparent in these male mice, no statistically significant body weight differential could be shown (12).

In this study, we subjected Ghrl–/– mice to a HFD 3 weeks after weaning in an attempt to accentuate the phenotype of these mice. The results of these studies show that male Ghrl–/– mice exposed to a HFD at an early age maintain a lean phenotype in association with increased energy expenditure and locomotor activity, suggesting that ghrelin plays an important role in regulating energy balance in young mice.


Reduced body weight gain and adiposity of male Ghrl–/– mice fed a HFD.

To study the effects of ghrelin deficiency on growth, development, and metabolic efficiency, Ghrl+/+ and Ghrl–/– mice were placed on a HFD 3 weeks after weaning (at approximately 6 weeks of age). Male Ghrl–/– mice showed no difference in body weight gain compared with littermate control mice (Ghrl+/+) when maintained on a standard chow diet (Figure (Figure1A).1A). In contrast, male Ghrl–/– mice that were switched to the HFD (45% fat) exhibited a markedly reduced rate of body weight gain over time. This resulted in an approximately 30% lower body weight in male Ghrl–/– mice at 24 weeks of age (Figure (Figure1,1, A and B), which is similar to the weight attained by the mice on the standard diet. In contrast to male mice, female Ghrl–/– mice maintained on the HFD 3 weeks after weaning did not demonstrate a difference in body weight gain compared with littermate control mice (data not shown).

Figure 1
Differential effects of diet on body weight and body composition in male Ghrl–/– mice. (A) Body weights of male Ghrl+/+ and Ghrl–/– mice maintained on standard (Std) diet were similar at 16 and 24 weeks ...

The consumption of a HFD fed ad libitum changes body composition and metabolic status and alters levels of cholesterol, triglycerides, and insulin in normal C57BL6/J mice. Analysis of body composition at 20 weeks of age showed that lean and fat mass of male Ghrl+/+ and Ghrl–/– mice were equivalent when maintained on the standard diet (Figure (Figure1C).1C). In the mice maintained on the HFD, absolute lean and fat mass were lower in the Ghrl–/– mice compared with the Ghrl+/+ mice, but when these measures were expressed as a percentage of total body weight, these changes reflected a specific decrease in percent adiposity, with no difference in percent lean mass between the 2 genotypes on this diet (lean mass: Ghrl+/+, 54.3% ± 0.9% vs. Ghrl–/–, 59.2% ± 2.4%, NS; fat mass: Ghrl+/+, 39.4% ± 0.9% vs. Ghrl–/–, 30.9% ± 3.5%, P < 0.05). Despite the robust difference in body composition noted above, no differences were apparent in body length (10.1 ± 0.08 cm vs. 9.9 ± 0.15 cm; NS) or absolute 24-hour food intake (Figure (Figure1D)1D) between male Ghrl+/+ and Ghrl–/– mice on the HFD. However, male Ghrl–/– mice on the HFD showed a trend (P = 0.06) toward decreased feed efficiency (defined as weight gain per kilocalorie consumed) compared with Ghrl+/+ mice (Figure (Figure11E).

Higher energy expenditure and activity in male Ghrl–/– mice on the HFD.

Eighteen-week-old male Ghrl–/– mice maintained on the standard diet showed no differences in respiratory quotient (RQ), energy expenditure, or home cage activity (Figure (Figure2,2, A, C, and E), compared with Ghrl+/+mice. When assessed after 3 months on the HFD, Ghrl+/+ and Ghrl–/– mice exhibited an equivalent reduction in RQ (Figure (Figure2B).2B). Despite the comparable level of lipid utilization, Ghrl–/– mice showed greater energy expenditure than Ghrl+/+ mice during both the dark and light periods (Figure (Figure2D).2D). This difference in energy expenditure was also apparent when energy expenditure was expressed on a per mouse basis (dark period: Ghrl+/+, 1.186 ± 0.047 kcal/h vs. Ghrl–/–, 1.307 ± 0.030 kcal/h, P = 0.0446; light period, Ghrl+/+, 0.973 ± 0.024 kcal/h vs. Ghrl–/– 1.118 ± 0.048 kcal/h, P = 0.0390). Part of this increased energy expenditure may be attributable to a greater level of locomotor activity compared with Ghrl+/+ mice on this diet, which was apparent specifically during the dark (active) period (Figure (Figure22F).

Figure 2
Metabolic parameters in 18-week-old male Ghrl–/– mice fed the standard diet or the HFD 3 weeks after weaning. RQs in male Ghrl+/+ and Ghrl–/– mice on the standard diet (A) and HFD (B) were similar. Energy ...

Male Ghrl–/– mice on a HFD exhibit an attenuated reduction in GH mRNA.

We analyzed the expression of pituitary transcripts for GH and liver transcripts for GH receptor (GHR) and IGF-1 in male mice at 6 months of age. On the standard diet, no differences in GH, IGF-1, or GHR mRNA were apparent between Ghrl+/+ and Ghrl–/– mice (Figure (Figure3).3). Ghrl+/+ mice on the HFD demonstrated a marked reduction in GH and GHR expression compared with Ghrl+/+ on a standard diet. However, Ghrl–/– mice on the HFD exhibited an attenuated reduction in GH mRNA, no reduction in GHR mRNA, and a trend toward increased IGF-1 mRNA levels (Figure (Figure33).

Figure 3
The GH/IGF-1 axis in 6-month-old male Ghrl–/– mice fed a standard diet or HFD 3 weeks after weaning. (A) Pituitary GH mRNA in Ghrl+/+ and Ghrl–/– mice on standard diet was similar, whereas on the HFD, GH ...

Improved serum profile in male Ghrl–/– mice on a HFD.

We investigated serum parameters in male mice at 24 weeks of age. Ghrl+/+ and Ghrl–/– mice maintained on standard chow showed no differences in various serum parameters, including glucose, insulin, and lipids (Table (Table1).1). These mice also showed similar glucose tolerance and insulin sensitivity (data not shown). In addition to the their increase in body weight and adiposity, Ghrl+/+ mice fed the HFD demonstrated the expected increase in leptin, insulin, glucose, cholesterol, and alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio. Serum levels of IGF-1 were not different between the genotypes on either diet (Table (Table1).1). Despite their lower accrual of body fat during exposure to the HFD, Ghrl–/– mice also exhibited elevated levels of leptin, glucose, and cholesterol on the HFD, although these measures were significantly lower than those of Ghrl+/+ mice on this diet (Table (Table1).1). Insulin and triglyceride levels were also significantly lower in Ghrl–/– mice compared with Ghrl+/+ mice on the HFD and, interestingly, also appeared lower compared with those of Ghrl–/– mice on the standard diet. These reduced insulin and triglyceride levels in the Ghrl–/– mice are consistent with the lower ALT/AST ratio of these mice on the HFD, which is a reflection of liver function and can be elevated in conditions of obesity (Table (Table1).1). Ghrl–/– mice on the HFD also exhibited improved glucose tolerance compared with Ghrl+/+ mice (data not shown).

Table 1
Serum parameters in male Ghrl+/+ and Ghrl–/– mice following a 4-hour fast


The discrepant findings between the physiological and genetic studies of ghrelin on food intake and body weight have raised questions about the value of ghrelin as a potential therapeutic target for obesity. Whereas ghrelin appears to have little impact on energy balance in mice exposed to a HFD as adults (10, 12), the present findings indicate that endogenous ghrelin plays a crucial role in regulating energy balance in male mice in response to early exposure at 6 weeks of age to a HFD.

We show that male Ghrl–/– mice switched to a HFD 3 weeks after weaning maintain a lean phenotype in adulthood. This finding extends our earlier data (12), which indicated a trend toward reduced body weight gain in older adult (18 weeks) Ghrl–/– mice placed on a HFD. The implications are that early exposure to a HFD is crucial to unmasking the resistance of Ghrl–/– mice to diet-induced obesity. In contrast to male mice, female Ghrl–/– mice placed on a HFD showed no difference in body composition compared with their wild-type counterparts. However, this finding could be due to the fact that these mice have a predominantly C57BL6/J (approximately 87.5%) background. In contrast to male C57BL6/J mice, female mice of this strain gain very little weight on a HFD, making it inherently difficult to detect a lean phenotype in female mice in this background strain.

Consistent with their reduced body weight gain and adiposity, male Ghrl–/– mice exhibited a trend for reduced feed efficiency. Although this finding was not statistically significant (P = 0.06), small differences in energy intake could contribute to the lean phenotype of these mice over time. Indeed, analyses of Ghsr–/– mice weaned onto a HFD do show a significant reduction in feed efficiency over time in association with reduced body weight and adiposity (13). We also investigated possible changes in metabolic parameters. We have shown previously that exposure of adult Ghrl–/– mice to a HFD has a dramatic effect, lowering RQ after only 6 weeks on the diet (12), indicating that these mice are able to adapt to lipid substrate utilization more rapidly than their wild-type counterparts. However, in the present study, Ghrl+/+ and Ghrl–/– mice exhibited an equivalent respiratory quotient after 3 months on the HFD. Nevertheless, Ghrl–/– mice exhibited greater energy expenditure and locomotor activity than Ghrl+/+ mice on the HFD. The increase in locomotor activity in the Ghrl–/– mice is consistent with exogenous ghrelin’s reported suppression of spontaneous locomotor activity (14). This phenomenon likely contributes to the increase in energy expenditure during the dark (active) period. However, the Ghrl–/– mice also showed increased energy expenditure during the resting period when no differences in activity are apparent, suggesting that these mice inappropriately expend calories during this period. Studies have revealed that Ghsr–/– mice weaned onto a HFD also exhibit reduced energetic efficiency (13). Together these findings suggest that the ghrelin/GHSR pathway plays an important role in enabling mice to adapt to changes in nutritional status by controlling metabolic parameters such as energy expenditure and locomotor activity.

Ghrelin stimulates the release of GH (1). However, the importance of endogenous ghrelin in regulating GH in vivo remains unclear. GH also has well-documented effects on body composition and energy expenditure (15). Thus, the differential response of ghrelin-deficient animals to a HFD may, in fact, be due to perturbation in the GH/IGF-1 axis. Whereas mice of both genotypes exhibited a downregulation of GH and GHR mRNAs on the HFD, GH levels in Ghrl–/– mice were significantly higher than those of their wild-type counterparts. Considering that ghrelin is defined as a GH-releasing peptide (1), these findings are somewhat surprising. However, they are reminiscent of changes in the GH/IGF-1 axis observed in human obesity, which are commonly characterized by blunted basal GH secretion (16, 17). That GH expression in Ghrl–/– mice is increased in association with reduced adiposity (relative to Ghrl+/+ mice on HFD) is also consistent with the reduced adiposity observed in rats with GH infusion (18) or in transgenic mice overexpressing GHSR in GH-releasing hormone neurons, which results in GH overexpression (19). Considering that ghrelin levels are reduced by prolonged exposure to a HFD (4, 5), these collective data suggest that endogenous ghrelin may form part of a pathway involved in modulating the GH/IGF-1 pathway in response to changes in nutrient availability, such as those induced by a HFD. The lack of an equivalent reduction in GH and GHR in Ghrl–/– mice on a HFD may reflect the loss of signaling from ghrelin in this pathway. Nevertheless, the finding that neither IGF-1 mRNA nor serum IGF-1 levels are significantly changed suggests that the perturbation in the GH/IGF-1 axis is most likely not responsible for the markedly lean phenotype of these mice.

In addition to decreased adiposity, conditions of elevated GH, such as acromegaly and GH overexpression in transgenic mice, are often accompanied by other abnormalities, such as insulin resistance and dyslipidemia (20). Thus, the higher expression of GH and GHR in the ghrelin-deficient mice on a HFD compared with their wild-type counterparts could lead to similar physiological changes. In contrast to these predictions, the Ghrl–/– mice on the HFD showed improved levels of insulin, glucose, and lipids compared with wild-type mice on this diet and exhibited greater glucose tolerance. Therefore, Ghrl–/– mice showed no signs of insulin resistance or dyslipidemia, and we conclude that the changes in serum parameters are unlikely to be related to changes in GH expression and are more likely to be a direct result of the decreased adiposity of these mice. Thus, as opposed to a condition of elevated GH, the Ghrl–/– mice on a HFD more accurately reflect the maintenance of the GH/IGF-1 axis activity.

Hypothalamic neuropeptide systems that control food intake and metabolism undergo dynamic changes during the postnatal period (21, 22). Given that ghrelin has well-established effects on NPY/AgRP neurons in the hypothalamus (8, 9, 23), it is plausible that the absence of ghrelin, like leptin (24), can impact on the functional organization of these pathways during development and alter the sensitivity of these pathways to subsequent changes in nutritional status. We would postulate that the effect of ghrelin on these metabolic pathways during development is likely to be mediated via the hypothalamic GHSR, since hypothalamus-specific Ghsr-deficient mice show a similar lean phenotype following early exposure to a HFD (13). Thus, our data, together with those of Zigman et al. (13), suggests that the absence of ghrelin signaling provides protection against diet-induced obesity induced by early exposure to a HFD, possibly due to dynamic changes in hypothalamic neuropeptide signaling (21, 22). It is not clear, however, why male Ghrl–/– mice exposed to a HFD 3 weeks after weaning maintain a lean phenotype, whereas older adult Ghrl–/– mice remain susceptible to diet-induced obesity (10, 12). Nevertheless, it is well established that early-life nutrition has a profound impact on body weight, metabolism, long-term adiposity (25, 26), and even, longevity in mice (27).

In summary, we propose that ghrelin is a hormone that functions to protect against the debilitating effects of undernutrition by stimulating appetite and minimizing activity to conserve energy stores. In Western societies, humans typically consume diets very rich in fat and in overall caloric content. In this setting, the inability of the body to totally inhibit ghrelin’s actions may not constitute a beneficial adaptive mechanism. Rather, ghrelin may contribute to a further increase in positive energy balance. Whereas the complete suppression of ghrelin would yield little evolutionary benefit for animals, the pharmacological inhibition of ghrelin action in humans provides a new avenue for antiobesity research.



Ghrl–/– mice were generated using the previously described high-throughput homologous recombination technology termed Velocigene (12, 28). After germ line transmission was established, mice were backcrossed to C57BL6/J mice to generate N3 breeding heterozygote mice that were set up in triads of 1 male and 2 females to generate homozygous null mice. All experiments reported were conducted on such N3F2 littermates, which were housed under 12 hours of light per day in a temperature-controlled environment. The average litter size was 7.3 pups per triad, and mice were weaned at 21 days of age. All procedures were approved by the Regeneron Institutional Animal Care and Use Committee. Animals had free access to either standard chow (5020; Purina) or HFD (45% fat, 4.7 kcal/g; 93075, Harlan Teklad).

Indirect calorimetry, food intake, and body composition.

Metabolic parameters were obtained using an Oxymax (Columbus Instruments) open-circuit indirect calorimetry system as previously described (29). Briefly, O2 consumed (ml/kg/h) and CO2 generated (ml/kg/h) by each animal were measured for a 48-hour period, and metabolic rate (VO2) and RQ (ratio of VCO2 to VO2) were then calculated. Activity (counts) was also measured during the 48-hour period. Energy expenditure (or heat) was calculated as the product of the calorific value of oxygen (= 3.815 + 1.232 × RQ) and the volume of O2 consumed. The first 24-hour period allowed the mice to acclimate to the cages, and the data shown represent the second 24-hour period in the cages. Food intake was also assessed by automated measurements in metabolic cages, and body composition was determined in each individual animal utilizing dual-emission x-ray absorption (PIXImus; Lunar). The calculation of feed efficiency in mice fed the HFD was determined by dividing body weight gain by caloric intake over a 7-day period.

Tissue and serum analysis.

Serum samples were obtained from trunk blood taken following between 1300 and 1400 after a 4-hour fast and analyzed for glucose, triglycerides, cholesterol, ALT, and AST utilizing the Bayer 1650 blood chemistry analyzer. Nonesterified free fatty acids were analyzed by a diagnostic kit (Wako Pure Chemical Industries Ltd.) and insulin, leptin, and glucagon levels by LincoPlex (Linco Research Inc.). Serum total IGF-1 was measured using a diagnostic EIA kit (Diagnostic Systems Laboratories Inc.). GH, IGF-1, and GHR mRNA levels were measured by quantitative real-time RT-PCR as previously described (30, 31).

Data and statistics.

Data are expressed as mean ± SEM. Comparison of means was carried out using 2-tailed Student’s t test or ANOVA where appropriate, using the program StatView (Abacus Concepts). When a significant F ratio was obtained (significance P < 0.05), post-hoc analysis was conducted between groups using a multiple comparison procedure with Bonferroni/Dunn post-hoc comparison. P values less than 0.05 were considered significant.


We thank Melissa Meola for the coordinated breeding of the ghrelin-knockout mice and Brian Ephraim for assistance with graphics.


See the related Commentary beginning on page 3393.

Nonstandard abbreviations used: AgRP, agouti-related protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GH, growth hormone; GHR, GH receptor; GHSR, growth hormone secretagogue receptor; HFD, high-fat diet; NPY, neuropeptide Y; RQ, respiratory quotient.

Conflict of interest: The authors have declared that no conflict of interest exists.


1. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660. [PubMed]
2. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2002;407:908–913. [PubMed]
3. Nakazato M, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194–198. [PubMed]
4. Moesgaard SG, et al. Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach. Regul. Pept. 2004;120:261–267. [PubMed]
5. Lee HM, Wang G, Englander EW, Kojima M, Greeley GH., Jr Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology. 2002;143:185–190. [PubMed]
6. Willesen MG, Kristensen P, Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology. 1999;70:306–316. [PubMed]
7. Cone RD, et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord. 2001;25(Suppl. 5):S63–S67. [PubMed]
8. Cowley MA, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–661. [PubMed]
9. Seoane LM, et al. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology. 2003;144:544–551. [PubMed]
10. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol. Cell. Biol. 2003;23:7973–7981. [PMC free article] [PubMed]
11. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc. Natl. Acad. Sci. U. S. A. 2004;101:4679–4684. [PubMed]
12. Wortley KE, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc. Natl. Acad. Sci. U. S. A. 2004;101:8227–8232. [PubMed]
13. Zigman JM, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J. Clin. Invest. 2005;115:3564–3572. doi:10.1172/JCI26002. [PMC free article] [PubMed]
14. Tang-Christensen M, et al. Central administration of ghrelin and agouti-related protein (83–132) increases food intake and decreases spontaneous locomotor activity in rats. Endocrinology. 2004;145:4645–4652. [PubMed]
15. Mukherjee A, Murray RD, Shalet SM. Impact of growth hormone status on body composition and the skeleton. Horm. Res. 2004;62(Suppl. 3):35–41. [PubMed]
16. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int. J. Obes. Relat. Metab. Disord. 1999;23:260–271. [PubMed]
17. Veldhuis JD, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 1991;72:51–59. [PubMed]
18. Clark RG, et al. The obese growth hormone (GH)-deficient dwarf rat: body fat responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology. 1996;137:1904–1912. [PubMed]
19. Lall S, et al. Physiological studies of transgenic mice overexpressing growth hormone (GH) secretagogue receptor 1A in GH-releasing hormone neurons. Endocrinology. 2004;145:1602–1611. [PubMed]
20. Olsson B, et al. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology. 2005;146:920–930. [PubMed]
21. Grove KL, Allen S, Grayson BE, Smith MS. Postnatal development of the hypothalamic neuropeptide Y system. Neuroscience. 2003;116:393–406. [PubMed]
22. Grove KL, Smith MS. Ontogeny of the hypothalamic neuropeptide Y system. Physiol. Behav. 2003;79:47–63. [PubMed]
23. Chen HY, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004;145:2607–2612. [PubMed]
24. Pinto S, et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science. 2004;304:110–115. [PubMed]
25. Ozanne SE, Lewis R, Jennings BJ, Hales CN. Early programming of weight gain in mice prevents the induction of obesity by a highly palatable diet. Clin. Sci. (Lond.). 2004;106:141–145. [PubMed]
26. Velkoska E, Cole TJ, Morris MJ. Early dietary intervention: long-term effects on blood pressure, brain neuropeptide Y, and adiposity markers. Am. J. Physiol. Endocrinol. Metab. 2005;288:E1236–E1243. [PubMed]
27. Ozanne SE, Hales CN. Lifespan: catch-up growth and obesity in male mice. Nature. 2004;427:411–412. [PubMed]
28. Valenzuela DM, et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat. Biotechnol. 2003;21:652–659. [PubMed]
29. Sleeman MW, et al. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc. Natl. Acad. Sci. U. S. A. 2003;100:14297–14302. [PubMed]
30. Iida K, et al. Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-deficient (lit/lit) mice and transgenic mice that overexpress bovine GH (bGH) or a bGH antagonist. Endocrinology. 2004;145:1564–1570. [PubMed]
31. Iida K, Rosen CJ, Ackert-Bicknell C, Thorner MO. Genetic differences in the insulin-like growth factor-I (IGF-I) gene among inbred strains of mice with different serum IGF-I levels. J. Endocrinol. 2005;186:481–489. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation